详情页

当前位置：首页 > 详情页

9MW2821 + Toripalimab vs 9MW2821 for 1st Line Locally Advanced or Metastatic Urothelial Carcinoma

2| 认领 | 链接全文 |

文献详情

编号/登记号：

注册时间：

研究开始时间：

研究结束时间：

项目类型：

本院角色：

多中心研究：

招募状态：

试验分期：

研究疾病/适应症：

研究类型：

研究单位： [1]Mabwell (Shanghai) Bioscience Co., Ltd. [2]Beijing Chao-yang Hospital, Capital Medical University,Beijing,Beijing,China [3]Fujian Medical University Union Hospital,Fuzhou,Fujian,China [4]Fourth Hospital of Hebei Medical University,Shijiazhuang,Hebei,China [5]Hunan Tumor Hospital,Changsha,Hunan,China,410013 [6]Nanjing Drum Tower Hospital,Nanjing,Jiangsu,China,210000 [7]Jiangsu People''s Hospital,Nanjing,Jiangsu,China [8]Yantai Yuhuangding Hospital,Yantai,Shandong,China [9]Shao Yi Fu Hospital,Hangzhou,Zhejiang,China

关键词： 9MW2821

研究目的：

This study will compare the efficacy of 9MW2821+toripalimab versus 9MW2821 monotherapy in locally advanced or metastatic urothelial carcinoma patients who have not received any systemic treatment in the metastatic or advanced setting.